Streetbeat News

DNA

Ginkgo Bioworks Holdings, Inc.

https://www.ginkgobioworks.com

Industry

Biotechnology

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks has a partnership with Selecta Biosciences, Inc. to develop ImmTOR technology platform. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Open

8.30

Mkt cap

472M

Volume

498K

High

8.56

P/E Ratio

-0.47

52-wk high

75.20

Low

8.13

Div yield

N/A

52-wk low

5.26

Ginkgo Bioworks anticipates adding 100-120 new cell programs to its cell engineering platform in 2024, with expected total revenue ranging between $215M-$235M, which is below the estimated $279.546M.

Portfolio Pulse from Benzinga Newsdesk

February 29, 2024 | 10:04 pm

Ginkgo Bioworks Holdings (NYSE:DNA) reported Q4 earnings with a loss of $(0.11) per share, missing the $(0.10) estimate, and sales of $34.76M, missing the $42.50M estimate. This represents a 10% increase in losses and an 18.22% miss in sales estimates compared to the same period last year, alongside a 64.64% decrease in sales from $98.28M.

Portfolio Pulse from Benzinga Newsdesk

February 29, 2024 | 10:02 pm

Numerous companies are scheduled to report their earnings on February 29, 2024, covering a wide range of industries from technology to healthcare. This includes both expected quarterly profits and losses, with significant revenues anticipated for some. The diversity of sectors represented, from energy to financial services, highlights the broad economic implications of these reports.

Portfolio Pulse from Benzinga Insights

February 29, 2024 | 10:15 am

Ginkgo Bioworks Holdings (NYSE:DNA) is scheduled to release its quarterly earnings report on Thursday, 2024-02-29, with an expected EPS of $-0.10. Investors are hopeful for a beat on this estimate and positive guidance for the next quarter. The company's past earnings performance shows a pattern of not meeting EPS estimates, leading to significant price drops. Shares are currently trading at $1.53, with a 9.28% increase over the last 52 weeks.

Portfolio Pulse from Benzinga Insights

February 28, 2024 | 3:01 pm

Ginkgo Bioworks has acquired key assets of Reverie Labs, including infrastructure and software for AI/ML drug discovery acceleration. Four of Reverie's AI team members will also join Ginkgo.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 12:30 pm

Ginkgo Bioworks awarded $4.29M in restricted stock units to eight Patch Bio employees and $3.53M to four Reverie employees, related to acquisitions of Patch Biosciences and Reverie Labs on February 26 and February 23, respectively.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 12:28 pm

Ginkgo Bioworks has acquired Patch Biosciences, a company known for its AI platform for sequence design. The financial terms of the deal were not disclosed. Patch Biosciences had investment backing from notable firms including Andreessen Horowitz (a16z) Bio + Health, Casdin Capital, and S32.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 12:23 pm

bit.bio has been announced as the inaugural partner of Ginkgo Bioworks' new technology network. This partnership will allow bit.bio's ioCells portfolio of human cells, designed for research and drug discovery, to be integrated into Ginkgo's platform ecosystem.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 12:15 pm

Ginkgo Bioworks and SaponiQx, a subsidiary of Agenus Inc (NASDAQ: AGEN), have been awarded a 5-year contract by the MCDC, worth up to $31M, to discover and manufacture next-generation vaccine adjuvants using generative molecular design.

Portfolio Pulse from Benzinga Newsdesk

February 15, 2024 | 12:10 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.